IgA Nephropathy Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Urine Test is the fastest growing sector, North America is the largest market

The Global IgA Nephropathy Disease Treatment Market is projected to expand from USD 173.75 Million in 2025 to USD 241.08 Million by 2031, achieving a compound annual growth rate of 5.61%. Treatment regimens currently involve specialized pharmacotherapies such as corticosteroids, immunosuppressants, and emerging targeted agents like endothelin receptor antagonists, all aiming to reduce proteinuria and forestall the onset of end-stage renal disease. The sector's growth is fundamentally driven by the increasing global prevalence of autoimmune kidney disorders and a strengthened regulatory emphasis on orphan drug designations, which encourages pharmaceutical investment in disease-modifying therapies. These core drivers represent structural changes in clinical needs and approval processes rather than fleeting market trends, underpinning sustainable industry development.

However, market expansion faces a substantial hurdle in the form of widespread diagnostic delays, as the often asymptomatic presentation of the disease causes patients to miss critical therapeutic windows, thereby diminishing treatment effectiveness. This latency in diagnosis considerably narrows the pool of patients eligible for early-stage interventions. Data from the American Kidney Fund in 2025 indicates that IgA nephropathy impacts approximately 200,000 individuals in the United States, a figure that highlights a significant yet frequently undiagnosed population in need of accessible, long-term management solutions.

Market Drivers

The introduction of novel drug approvals and commercial launches acts as a primary engine for market growth, signifying a shift from palliative care to targeted disease modification. Regulatory bodies have expedited pathways for therapies addressing the specific pathogenesis of the condition, leading to rapid commercial adoption and immediate revenue for approved agents. This trend is evidenced by the robust market performance of recently authorized treatments, as reported by Travere Therapeutics in October 2024; the company announced net product sales of $35.6 million for FILSPARI in their third-quarter results, reflecting strong uptake of non-immunosuppressive therapies. Such revenue figures confirm that healthcare systems are willing to reimburse high-cost agents that prove effective in preserving kidney function and delaying dialysis.

Furthermore, the sector is propelled by strategic pharmaceutical partnerships and major acquisitions, as industry leaders invest heavily to secure high-potential clinical assets. This trend of consolidation highlights the premium placed on late-stage biologics that target autoimmune mechanisms, driving up valuation benchmarks. For instance, in April 2024, Vertex Pharmaceuticals entered a definitive agreement to acquire Alpine Immune Sciences for approximately $4.9 billion in cash to obtain povetacicept, a dual antagonist of BAFF and APRIL, thereby accelerating the development of next-generation immunotherapies. Clinical efficacy remains paramount for these investments, as demonstrated by Novartis in 2024, where the Phase III APPLAUSE-IgAN analysis showed that Fabhalta reduced proteinuria by 44% at nine months compared to placebo, setting a high bar for future market entrants.

Market Challenges

A critical obstacle hindering the Global IgA Nephropathy Disease Treatment Market is the high frequency of delayed diagnosis. Since the condition often progresses without obvious symptoms, patients frequently miss the ideal timeframe for early-stage interventions, which are the primary target of recent pharmaceutical developments. This diagnostic lag effectively shrinks the addressable market size, as clinicians are unable to prescribe disease-modifying pharmacotherapies to undiagnosed individuals. Consequently, the commercial adoption of high-value targeted agents is artificially suppressed, limiting the return on investment for drug developers and decelerating the overall pace of industry expansion.

The severity of underdiagnosis is highlighted by the prevalence of unacknowledged renal conditions, which is closely tied to the asymptomatic nature of IgA nephropathy. According to the National Kidney Foundation in 2024, nearly 90% of the 37 million adults with chronic kidney disease in the United States were unaware of their condition. Given that IgA nephropathy is a frequent underlying cause of this broader disease burden, this statistic reveals a vast pool of patients who require treatment but remain inaccessible to the market. This widespread lack of awareness directly impedes market proliferation by preventing the timely implementation of necessary long-term management strategies.

Market Trends

The market is increasingly pivoting toward targeted B-cell immunomodulators that address the core pathogenesis of IgA nephropathy by inhibiting the production of galactose-deficient IgA1. In contrast to broad-spectrum immunosuppression, these advanced agents specifically disrupt the survival signals of antibody-producing plasma cells, preventing the formation of nephrotoxic immune complexes that trigger glomerular inflammation. This mechanism-focused strategy supports the potential for long-term disease stabilization rather than just symptom control, as seen in Vera Therapeutics' October 2024 announcement regarding the ORIGIN Phase 2b study; the data revealed that atacicept administration led to a 66% reduction in galactose-deficient IgA1 and stabilized kidney function, validating the targeting of BAFF and APRIL pathways.

Concurrently, there is a strong emphasis on developing oral formulations for chronic disease management, driven by the need for patient-friendly regimens that support adherence over decades. Pharmaceutical engineers are creating oral therapeutics with sophisticated delivery systems, such as targeted delayed-release mechanisms that release active ingredients in the ileum to maximize local efficacy while minimizing systemic side effects. This shift toward convenient, self-administered therapies is altering prescription habits as providers look to reduce the logistical challenges of infusion-based biologics. This trend is underscored by Calliditas Therapeutics' interim report from August 2024, which noted net sales of SEK 493.4 million for TARPEYO in the second quarter, highlighting the significant commercial demand for oral agents capable of precise immunomodulation.

Key Market Players

• Travere Therapeutics Inc
• Calliditas Therapeutics AB
• Omeros Pharma Corporation
• Novartis Pharmaceuticals
• Chinook Therapeutics, Inc.
• Vera Therapeutics, Inc.
• Merck KGaA
• Reata Pharmaceuticals, Inc.
• Ionis Pharmaceuticals
• Apellis Pharmaceuticals

Report Scope

In this report, the Global IgA Nephropathy Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

IgA Nephropathy Disease Treatment Market, by Test:

• Blood Test
• Urine Test
• Kidney Biopsy
• Iothalamate Clearance Test
• Others

IgA Nephropathy Disease Treatment Market, by Treatment Type:

• Corticosteroids
• Immunosuppressive Drugs
• ACE Inhibitors And ARBs
• Diet Change
• Therapy

IgA Nephropathy Disease Treatment Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global IgA Nephropathy Disease Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.